Employees: 172
Size Shouyao Holdings Beijing (688197.SS) is a China Health Care company (Biotechnology) with a market value of $653M, the 3054th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.05 on 18 Nov 2026.
Performance Over six months the shares fell 25.6%, against -14.7% for the median peer and -20.0% for the China market (cap-weighted) — 7th lowest of 18 in its peer set.
Growth Revenue grew 4,563.9% over the last twelve months (peer median +18.1%); the operating margin is -92.0% (peer median -78.3%).
Valuation It trades at 38.1× enterprise value to sales against a peer median of 6.9× (4th most expensive of 16).
Capital Return on invested capital runs 83.2 points below its cost of capital (9.8% WACC).
Next results Next results expected around 3 May 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥99.9M | CN¥8.67M | CN¥3.94M | CN¥5.23M | CN¥1.83M |
| Revenue growth | — | +120% | -25% | +186% | — |
| Gross profit | n/a | CN¥620,372 | -CN¥3.29M | -CN¥2.45M | -CN¥4.95M |
| EBITDA | n/a | -CN¥200M | -CN¥225M | -CN¥211M | -CN¥212M |
| Net income | -CN¥18.6M | -CN¥129M | -CN¥212M | -CN¥186M | -CN¥174M |
| Free cash flow | -CN¥119M | -CN¥140M | -CN¥190M | -CN¥183M | -CN¥150M |
| Capital expenditure | CN¥38.3M | CN¥3.20M | CN¥8.57M | CN¥3.83M | CN¥20.7M |
| Total debt | CN¥7.36M | CN¥13.6M | CN¥6.48M | CN¥3.04M | CN¥8.09M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688197.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.1% | -7.3% | 8th highest of 21 |
| 6-month return | -25.6% | -14.7% | 7th lowest of 18 |
| Distance from 52-week high | -32.9% | -46.1% | 4th highest of 21 |
| Revenue growth (TTM) | +4,563.9% | +18.1% | highest of 16 |
| Operating margin | -92.0% | -78.3% | 9th highest of 17 |
| EV / Sales | 38.1× | 6.9× | 4th most expensive of 16 |
| ROIC minus cost of capital | -83.2 pp | -14.9 pp | 3rd lowest of 12 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shouyao Holdings Beijing 688197.SS | China | $653M | -26% | +4,564% | -92% | 38.1× | n/a | n/a |
| Frontier Biotechnologies 688221.SS | China | $658M | -48% | +153% | -20% | 11.4× | 40.3% | +21.5% |
| Alphamab Oncology 9966.HK | Hong Kong | $666M | -38% | -32% | -38% | 6.7× | n/a | n/a |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $668M | +292% | n/a | n/a | n/a | n/a | n/a |
| Geron GERN | United States | $638M | -21% | +19% | -8% | 2.8× | n/a | n/a |
| Shenzhen Weiguang Biological Products 002880.SZ | China | $633M | -27% | 0% | 18% | 4.4× | n/a | n/a |
| Kura Oncology KURA | United States | $674M | -29% | -24% | -394% | 2.6× | n/a | n/a |
| Janux Therapeutics JANX | United States | $631M | -28% | +133% | -599% | n/a | n/a | n/a |
| Getein Biotech 603387.SS | China | $625M | -13% | +8% | 21% | 2.6× | -8.9% | -1.3% |
| Anhui Wanbang Pharmaceutical Technology 301520.SZ | China | $684M | +74% | -15% | -8% | 14.7× | 44.8% | +14.7% |
| Prime Medicine PRME | United States | $695M | +35% | +18% | -2,584% | 105.4× | n/a | n/a |
| Design Therapeutics DSGN | United States | $606M | -15% | n/a | n/a | n/a | n/a | n/a |
| Surrozen SRZN | United States | $605M | +17% | +192% | -485% | 48.5× | n/a | n/a |
| Anhui Huaheng Biotechnology 688639.SS | China | $605M | -45% | +7% | 3% | 1.9× | n/a | n/a |
| Solid Biosciences SLDB | United States | $709M | -2% | n/a | n/a | n/a | n/a | n/a |
| Attovia Therapeutics ATTO | United States | $710M | +1,325% | n/a | -5,945% | 220.7× | n/a | n/a |
| Shaanxi Micot Pharmaceutical Technology 2335.HK | Hong Kong | $715M | n/a | n/a | n/a | n/a | n/a | n/a |
| Alebund Pharmaceuticals (Jiangsu) 9637.HK | Hong Kong | $595M | n/a | +674% | -495% | 26.8× | n/a | n/a |
| R&G PharmaStudies 301333.SZ | China | $722M | -11% | +21% | 11% | 3.4× | 17.3% | +11.8% |
| Apnimed APMD | United States | $726M | n/a | +380% | -140% | 10.8× | n/a | n/a |
| Beijing SL Pharmaceutical 002038.SZ | China | $736M | -20% | -4% | -119% | 6.9× | -13.5% | -10.9% |